Product Description
Mechanisms of Action: PA
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lung Biotechnology PBC
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BEAT OLE | P3 |
Terminated |
Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary |
2019-07-20 |
86% |
| Compassionate use BPS-314d-MR | P2 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2019-06-02 |
|
| BEAT | P3 |
Completed |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2019-02-19 |
|
| BPS-314d-MR-PAH-301 | P3 |
Withdrawn |
Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension |
2016-03-01 |